Drug Trial Radar · NCT06365788
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
53
Planned (sponsor's estimate)
Start
Apr 8, 2024
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kom Op Tegen Kanker; Eli Lilly and Company; Teva Pharma
- First posted
- Apr 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.
Conditions
- Triple Negative Breast Neoplasms
Interventions
AbemaciclibDrug
150 mg tablet orally twice daily
BicalutamideDrug
150 mg tablet orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with disease control at 16 weeksTime frame: Week 16
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
ZAS Augustinus
Antwerp, Belgium · Recruiting
Antwerp University Hospital
Antwerp, Belgium · Not yet recruiting
University Hospital Brussels
Brussels, Belgium · Recruiting
Ghent University Hospital
Ghent, Belgium · Recruiting
Jessa Ziekenhuis
Hasselt, Belgium · Recruiting
University Hospitals Leuven
Leuven, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.